Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Semax vs Noopept

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors Semax

Semax and Noopept are both Russian nootropics with only small open label human studies, but they reach users very differently. Semax is an intranasal peptide that is not FDA approved or on the 503A bulks list, but it is one of six peptides covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient intranasal compounding on a patient-specific prescription. Noopept is an oral piracetam relative that has never been nominated for compounding and is sold in the US as a supplement ingredient, which is not a lawful use.

Verified: Verified Oct 28, 2026
Semax nasal spraySponsoredFrom Bodybuilding Peptides

Which is better, Semax or Noopept?

The evidence is a tie: both are graded human observational from open Russian studies without placebo control (semax in stroke, Noopept in mild cognitive impairment after stroke or brain injury). Regulatory status breaks it. Semax is covered by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), which is not binding, while Noopept is not covered, is not compoundable, and its supplement sales are not an approved use, so product identity and purity are unverified. [1] [2] [3] [4] [5] [6] [13]

How do Semax and Noopept compare?

Semax and Noopept compared by dimension
DimensionSemaxFavoredNoopept
What it is [7] [8]Heptapeptide analog of ACTH fragment 4-10 with a stabilizing Pro-Gly-Pro tail.Synthetic dipeptide-like compound (phenylacetyl proline-glycine ethyl ester) related to piracetam, metabolized to cycloprolylglycine.
Proposed mechanism [7] [8] [9]Raised hippocampal BDNF and trkB in rats after one intranasal dose; monoamine and anti-ischemic effects in rodents.Raises BDNF and NGF in rodent hippocampus, enhances inhibitory transmission via alpha-7 nicotinic receptors on interneurons, and reduced tau hyperphosphorylation in a cell model.
Human evidence [1] [2] [3] [10]Open comparative Russian studies in acute ischemic stroke and chronic cerebrovascular insufficiency; no blinding or placebo.Open comparison with piracetam in mild cognitive disorders of vascular or traumatic origin, and an open study of 60 stroke patients reporting better MMSE scores after 2 months versus untreated controls.
Route [1] [2]Intranasal drops (Russian product and most sold forms).Oral tablet (Russian product) or capsule and powder (US supplement market).
Doses in the literature [1] [2]Intranasal 12 to 18 mg per day for 5 to 10 days in acute stroke; roughly 0.2 to 2 mg per day for cognitive uses.10 mg orally twice daily (20 mg per day) for 2 months.
FDA and compounding status [4] [5] [6] [11] [13] [14]Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (intranasal only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).Never nominated for the 503A or 503B bulks lists, not on the Category 2 page, and not covered by HHS's October 2026 draft policy; not compoundable. Sold as a supplement ingredient, which is not an approved use for a synthetic drug substance.
Access and cost [4] [6] [13]No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price.Sold online as an unapproved supplement that is not verified for identity or purity; no licensed pharmacy or telehealth channel.
Reported side effects [1] [2]Nasal irritation; anxiety, irritability, or insomnia reported anecdotally.Irritability, sleep disturbance, and headache reported anecdotally; blood pressure increases in some patients in Russian reports.
WADA status [12]Not named on the WADA Prohibited List; whether it falls under S0 (non-approved substances) is unclear, so tested athletes should confirm with their anti-doping organization.Not named on the WADA Prohibited List; status unclear, so tested athletes should confirm with their anti-doping organization.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Semax and Noopept: grade, status, and cost
AttributeSemaxNoopept
ClassSynthetic heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro), a melanocortin derived nootropic and neuroprotective peptideSynthetic dipeptide-like nootropic (proline-glycine ethyl ester with a phenylacetyl group), structurally related to piracetam
What it isNasal peptide registered in Russia; rodent and Russian stroke trial data; not FDA approved; nasal use in HHS's October 2026 draft policy.A dipeptide-like memory drug approved in Russia, with small open-label human studies, no placebo-controlled RCT indexed in English, and no FDA review.
EvidenceEvidence: Human observational evidenceEvidence: Human observational evidence
FDA statusRegulatory: HHS interim policy (draft)Regulatory: Unscheduled
CompoundingSemax is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds semax when every condition is met: a single active ingredient only (no blends or stacks), the allowed route (intranasal only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add semax to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.Noopept is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list, so it is outside FDA's interim policy and a 503A pharmacy has no federal basis to compound it from bulk. It is not eligible for 503B outsourcing. FDA has issued warning letters treating noopept products sold online with health claims as unapproved new drugs. Products sold as supplements or research chemicals are not verified for identity or purity.
WADAWADA: WADA status unclearWADA: WADA status unclear
RoutesIntranasal drops (Russian product and most sold forms), Subcutaneous injection (as sold, no published human data)Oral tablet (Russian prescription product, 10 mg), Oral capsule or powder (sold in the United States as an unapproved supplement ingredient), Sublingual and intranasal use reported anecdotally (no studies)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient semax on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Sold as an unapproved supplement in the United States at roughly 15 to 40 USD per month; not available through licensed pharmacy or telehealth channels.
Last verified

Has Semax been tested directly against Noopept?

No published trial has compared Semax and Noopept directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do Semax and Noopept cost?

Typical cost of Semax and Noopept
DimensionSemaxNoopept
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient semax on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Sold as an unapproved supplement in the United States at roughly 15 to 40 USD per month; not available through licensed pharmacy or telehealth channels.
Price detailSemax price by channelPrice index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Semax page and the Noopept page.

Frequently asked questions

Is semax or Noopept better for memory?

Neither has a placebo controlled trial for memory. Noopept's human data are in mild cognitive impairment after stroke or brain injury (better MMSE scores versus untreated controls in an open study of 60 patients); semax's are in stroke recovery. Evidence in healthy adults is absent for both. [1] [2] [3]

Is Noopept a peptide?

Not strictly. It is a small synthetic dipeptide-like molecule related to piracetam that is metabolized to the natural dipeptide cycloprolylglycine. Semax is a true seven amino acid peptide. [7] [8]

Is it legal to buy Noopept as a supplement?

It is sold that way, but a synthetic drug substance approved as a medicine in Russia does not meet the definition of a dietary ingredient, so the sale is not an approved use and products are not verified for identity or purity. Noopept also cannot be compounded, because it has never been nominated for the bulks lists. [5] [6]

Can a US pharmacy compound semax?

Possibly, under conditions. Semax is not FDA approved or on the 503A bulks list, but it is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (intranasal only) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Research-use-only products sold for human use are still unlawful, and state law still applies. [4] [11] [13] [14]

Are either banned in sport?

Neither is named on the WADA Prohibited List. Tested athletes should confirm with their anti-doping organization, because unapproved substances can fall under S0. [12]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997PubMed 11517472, 1997
  2. [2]Amelin AV et al. Noopept in the treatment of mild cognitive impairment in patients with stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2011 (Russian)PubMed 22500312, 2011
  3. [3]Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol 2009PubMed 19234797, 2009
  4. [4]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  5. [5]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
  6. [6]FDA: Compounding and the FDA, questions and answersFDA, 2026
  7. [7]Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006PubMed 16996037, 2006
  8. [8]Ostrovskaya RU et al. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci 2014PubMed 25096780, 2014
  9. [9]Kondratenko RV et al. Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves alpha-7 AChRs on interneurons in hippocampal slices from rat. Neurosci Lett 2022PubMed 36195298, 2022
  10. [10]Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2005PubMed 15792140, 2005

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Semax vs Noopept: evidence, cost, and legality. https://peptideagent.ai/compare/semax-vs-noopept
HTML link
<a href="https://peptideagent.ai/compare/semax-vs-noopept">Semax vs Noopept: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.